Alnylam positive reaction to guidance ‘makes sense,’ says JPMorgan

After Alnylam (ALNY) CEO Yvonne Greenstreet presented at the JPMorgan Healthcare Conference, JPMorgan thinks the Street will “continue to debate to some degree exactly how/where Amvuttra will be used in ATTR-CM,” but believes today’s positive stock reaction “makes sense” given the company’s above-consensus preliminary FY24 net product revenue outlook and 2025 guidance. The firm maintains a Neutral rating on Alnylam shares despite stating that it sees Alnylam “boasting an attractive platform and portfolio.”